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Abstract  Lymphoma  staging  systematically  includes  a  CT  scan  of  the  cervical,  thoracic  and
abdominopelvic  regions.  PET  is  indicated  in  diffuse  large  B  cell  lymphomas  (DLBCL)  and
Hodgkin’s  disease.  Evaluation  of  the  response  to  treatment  is  based  on  Cheson’s  1999  morpholog-
ical criteria,  which  have  been  replaced  by  the  2007  IWC  criteria,  which  combine  morphological
and metabolic  responses.  CT  and  FDG-PET  are  complementary  in  characterizing  residual  masses:
if negative,  a  PET  scan  indicates  the  absence  of  residual  disease,  if  positive;  it  directs  a
CT-guided  biopsy  to  obtain  the  histological  evidence.  Monitoring  clinical  features  and  labo-
ratory values  is  primordial  following  treatment.  Imaging  is  performed  as  a  second  intention  for
investigating  a  relapse,  if  necessary  associated  with  a  PET  scan.  Multimodal  imaging  implies
multidisciplinary  consultation  between  haematologists,  imaging  specialists  and  histopatholo-
gists.
© 2013  Published  by  Elsevier  Masson  SAS  on  behalf  of  the  Éditions  françaises  de  radiologie.
A  lymphocyte  may  evolve  towards  a  tumoral  process  at  any  stage  in  its  differen-
tiation  thus  inducing  a  lymphoma  with  characteristics  directly  related  to  the  degree
of  its  differentiation.  The  great  diversity  in  the  stages  of  lymphopoiesis  (B  and  T-cell)
explains  the  wide  range  of  lymphomas,  de  facto  with  clinical  and  therapeutic  diversity.
The  WHO  classiﬁcation  of  lymphomas  is  based  on  this  connection  between  the  tumour
cell  and  its  normal  equivalent,  which  necessitates  characterization  of  malignant  lympho-
cytes  —  morphological,  histological,  phenotypic,  cytogenetic  and  molecular  —  that  is  as
complete  as  possible.  Since  diagnosis  and  therapeutic  management  depend  on  this  stage
characterizing  the  malignant  cell,  it  is  essential,  for  the  most  complete  exploitation  pos-
sible,  which  must  be  performed  by  a  competent  histopathology  team,  to  have  a  biopsy
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adaptation  of  treatment,  either  for  increasing  treatment  in46  
ample  of  optimal  quality  right  from  the  time  of  diagnosis.  In
rance,  the  ‘‘lymphopath’’  network  provides  this  expertise
hroughout  the  country.
Given  the  obvious  diverse  nature  of  lymphomas,  it  is
mportant  to  remember  a  few  major  facts.  Lymphomas  can
e  divided  into  two  large  groups  with  Hodgkin’s  lymphomas
HL)  (or  Hodgkin’s  disease)  on  one  hand,  and  malignant  non-
odgkin’s  lymphomas  (NHL)  on  the  other.  In  the  second
roup,  85%  of  proliferations  arise  from  the  B  line  (B  lym-
homas)  against  only  15%  from  the  T  line  (T  lymphomas).
 and  T  lymphomas  can  then  be  subdivided  into  various
ntities  depending  on  the  degree  of  differentiation  of  the
ymphocyte.
We  often  speak  of  aggressive  lymphomas  and  indo-
ent  lymphomas.  This  is  a  purely  clinical  view,  which
as  no  anatomical  or  pathological  basis.  It  can  be  said
hat  aggressive  lymphomas,  diffuse  large  B  cell  lymphomas
DLBCL)  or  Burkitt’s  lymphoma  for  example,  are  generally
ery  chemosensitive  and  present  unfrequently  a  long  term
elapse.  In  contrast,  indolent  lymphomas  present  more  fre-
uently  relapses  despite  a  relative  chemosentivity.  This  is
 rather  ‘‘caricatural’’  view  of  lymphomas  but  is  based  on
linical  observations.  The  therapeutic  progress  of  recent
ears  has  shown  that  a  cure  is  a  realistic  objective  in  the
arge  majority  of  lymphomas:  Hodgkin’s  disease,  DLBCL,
urkitt’s  lymphoma.
Staging  a  lymphomatous  disease  consists  of  standard  lab-
ratory  examinations  with  the  addition  of  imaging.  The
atter  systematically  includes  a  thoraco-abdominopelvic  CT
can,  and  if  necessary  a  cervical  scan,  with  injection  of
n  iodinated  contrast  agent.  Positron  emission  tomography
PET)  is  not  substituted  for  a  CT  scan,  but  is  combined  with
T  in  just  two  histological  types  of  lymphomas  with  high
vidity  for  FDG:  DLBCL  and  Hodgkin’s  disease  [1].  Apart  from
hese  two  conditions,  the  systematic  use  of  PET  in  staging  is
ot  based  on  any  international  recommendation.  However,
ET  may  be  discussed  case  by  case,  particularly  when  an
ggressive  transformation  is  suspected.  Transformed  areas
sually  have  greater  avidity  for  FDG  than  untransformed
reas.  A  PET  scan  can  also  be  suggested  in  the  initial  stag-
ng  of  follicular  lymphoma  for  which  radiotherapy  may  be
n  alternative  treatment.
igure 1. Grade II follicular lymphoma, systematic monitoring. a: CT s
ogical conﬁrmation of transformation into diffuse large B cell lymphom
s
p
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The  emergence  over  the  past  few  years  of  metabolic
maging  techniques  has  thus  modiﬁed  the  relationship
etween  haematology  and  imaging,  but  conventional  radi-
logy  retains  an  essential  role  in  the  care  of  the  patient,
rom  initial  diagnosis  to  monitoring.  CT  and  FDG-PET  are
omplementary  [2]  particularly  in  characterizing  lesions,
ecause  metabolic  imaging  can  direct  CT-guided  biopsy,
y  identifying  residual  masses  or  by  authenticating  the
ransformation  of  an  indolent  lymphoma  into  a  high-grade
ymphoma  (Fig.  1).  These  decisions  concerning  invasive
iagnostic  procedures  are  taken  during  multidisciplinary
eetings  between  haematologists,  histopathologists,  radio-
herapists  and  radiologists  [3,4]. It  is  essential  for  the
maging  specialist  to  understand  the  therapeutic  issues  when
iscussing  with  the  haematologist  who  will  adapt  and  eval-
ate  the  treatment  depending  on  the  images  and  on  the
linical  criteria  and  laboratory  values,  with  the  objective  of
roviding  curative  treatment  in  aggressive  lymphomas  [5].
valuation of response of the tumour to
reatment
valuation  of  the  response  to  treatment  relies  very  largely
n  the  CT  evaluation  measuring  the  reduction  in  target
esions  deﬁned  in  the  diagnosis.
Sometimes  undertaking  intermediate  examinations  may
e  discussed  to  assess  the  response  after  only  a  few  courses
f  chemotherapy.  Such  examinations  including  a  CT  scan
nd/or  ultrasonography  are  above  all  relevant  for  the  most
ggressive  lymphomas  (DLBCL,  Hodgkin’s  disease,  mantle
ell  lymphomas,  etc.).  The  point  of  an  intermediate  exam-
nation  is  more  questionable  in  indolent  lymphomas,  which
re  usually  chemosensitive.  On  the  other  hand,  PET  is  being
sed  more  and  more  in  intermediate  examinations  although
ts  most  documented  indication  in  the  literature  is  limited  to
odgkin’s  disease  or  DLBCL.  Moreover,  the  present  trend  is  to
ncreasingly  perform  intermediate  PET  scans  to  allow  earlycan: appearance of a pelvic mass; b: CT-guided biopsy: histopatho-
a.
low  responders  or  for  decreasing  it  in  the  most  responsive
atients.  The  question  of  intermediate  examinations  using
ET  scans  is  still  being  studied.
i
t
i
i
m
w
l
m
i
I
T
e
m
a
l
d
g
i
R
t
t
e
c
t
a
t
d
s
o
t
c
CStaging  and  monitoring  in  the  treatment  of  lymphomas  
At  the  initial  stage  of  the  disease,  therapeutic  manage-
ment  is  based  on  the  Ann  Arbor  classiﬁcation,  which  itself
is  largely  based  on  the  CT/FDG-PET  combination,  an  essen-
tial  step  in  carrying  out  a  precise  evaluation  of  the  tumour
response,  combining  imaging  with  clinical  and  laboratory
data  —  IPI  and  FLIPI  scores  [6].  The  standardised  interna-
tional  criteria  for  the  morphological  response  of  lymphomas
refer  to  Cheson’s  classiﬁcation  with  two-dimensional  mea-
surements  from  the  thoraco-abdominopelvic  CT  scan,  and
differ  from  the  single-dimension  criteria  of  the  RECIST  1.1
solid  tumour  classiﬁcation.
Evaluation  of  the  response  of  lymphomas  to  treatment
has  evolved  over  two  periods,  determined  by  the  arrival  of
FDG-PET.  The  Cheson  1999  morphological  criteria  [7],  estab-
lished  from  a  CT  scan,  which  used  to  be  the  only  imaging
procedure  for  initial  staging  and  evaluation,  were  modiﬁed
and  updated  between  2005  and  2007  [8,9]  to  take  PET  into
account,  providing  not  only  objective  response  criteria  but
also  prognostic  value  for  the  disease.  Since  then  they  have
consisted  therefore  of  evaluation  combining  a  CT  scan  with
injection  and  PET,  even  though  in  most  centres  these  are
two  examinations  performed  separately,  one  by  the  radiolo-
gist,  the  other  by  a  nuclear  medicine  specialist.  Synthesis  of
the  results  forms  the  standardised  evaluation  according  to
the  international  criteria  established  by  Juweid  and  Cheson
in  2005  then  2007.
Some  lymphomas,  however,  are  inconsistent  in  their
uptake  of  FDG  thus  limiting  the  usefulness  of  PET  in  cer-
tain  patients  with  T-cell  lymphoma  or  indolent  non-follicular
lymphoma  (MALT,  mantle  cell,  lymphocytic).  The  CT  scan
remains  the  initial  technique  for  diagnosis  and  during
evolution  under  treatment,  until  these  lymphomas  are  trans-
formed  into  high-grade  tumours,  when  they  become  eligible
for  PET  [10].
At  present,  CT  is  therefore  the  essential  feature  of  the
end  of  treatment  examination.  It  should  be  remembered
that  the  indication  for  a  PET  scan  at  the  end  of  treatment
currently  only  concerns  Hodgkin’s  disease  and  DLBCLs.  For
all  other  lymphopathies,  CT  remains  the  reference  tech-
nique.  While  PET  undeniably  makes  a  major  contribution  in
lymphomas,  the  risk  of  false  positives  must  also  be  taken
T
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Figure 2. Burkitt’s lymphoma in a 3-year-old child. a: initial CT scan: c
coeliac and retroperitoneal lymphadenopathies; b: end of treatment CT
lymph node lesions.147
nto  account,  resulting  in  the  CT  scan  being  maintained  in
he  end  of  treatment  examination.  Like  the  CT  scan  of  the
nitial  examination,  the  end  of  treatment  CT  scan  should
nclude  an  exhaustive  description  of  residual  masses,  which
ust  be  compared  with  the  initial  masses  and  associated
ith  numerical  measurement  of  tumour  reduction.  The  two
argest  dimensions  of  the  tumours  should  be  measured  and
ultiplied  together.  The  percentage  reduction  in  this  area
s  then  established,  between  monitoring  scans.
WC Cheson 1999 criteria [7]
he  morphological  response  in  the  end  of  treatment  CT
stablished  by  Cheson  in  1999  corresponds  to  the  recom-
endations  of  the  international  group  that  depends  on  the
natomical  deﬁnition  of  the  response  with  a  ‘‘normalised’’
ymph  node  dimension  of  1.5  cm  in  its  greatest  transverse
iameter.  Initially  on  diagnosis,  however,  a  lymph  node  the
reatest  transverse  diameter  of  which  is  more  than  1  cm
s  considered  as  possibly  indicating  lymphomatous  invasion.
egression  of  the  tumour  mass  of  the  lymph  node  following
reatment  is  accompanied  by  ﬁbrosis,  necrosis  or  inﬂamma-
ion  resulting  in  persistent  enlargement  of  the  lymph  nodes
ven  though  they  are  histologically  free  of  any  viable  tumour
ells.  It  should  be  noted  that  unlike  the  criteria  for  solid
umours  (RECIST),  lymphomatous  lymph  nodes  are  evalu-
ted  on  their  largest  transverse  diameter  for  deﬁning  return
o  normal.
Initial  and  post-treatment  measurements,  always  in  two
imensions,  are  made  on  axial  slices  on  two  perpendiculars
tarting  from  the  largest  transverse  diameter.
The  clinical,  laboratory  and  histopathological  parameters
f  the  bone  marrow,  taken  into  account  by  the  haematologist
o  assess  the  overall  response  are  added  to  the  morphologi-
al  response  criteria.
omplete  response
his  is  the  disappearance  of  all  measurable  lymph  node
r  extranodal  lesions  (Fig.  2).  All  nodal  masses  must  have
egressed  to  less  or  equal  to  1.5  cm  in  their  greatest
entro-hepatic and hepatic pedicle lymphomatous inﬁltration, with
 scan: complete response with disappearance of the hepatic and
1 B.  Dupas  et  al.
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Figure 4. Thoracic CT scan: pulmonary relapse in the left infe-
rior lobe after a complete response in a 29-year-old man. Biopsy
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ransverse  axis  for  lymph  nodes  initially  greater  than  1.5  cm
efore  treatment.  Lymph  nodes  with  a  greatest  diameter
f  between  1.1  and  1.5  cm  before  treatment  must  have
ecreased  to  less  than  1  cm  in  their  greatest  transverse
iameter  or  by  more  than  75%  of  the  sum  of  the  prod-
cts  of  the  greatest  diameters  (SPD).  No  measurable  nodule
ust  be  detectable  in  the  other  organs  affected  by  the
ymphoma  (the  spleen,  liver,  kidneys,  adrenal  glands,  lungs
tc.).
nconﬁrmed  complete  response
his  is  a  response  in  the  1999  CT  criteria,  now  deleted
ince  FDG-PET  inclusion  (Fig.  3).  It  corresponded  to
atients  with  complete  response  criteria  but  with  persis-
ence  of  a  residual  mass,  regression  of  which  was  more
han  75%  of  the  SPD,  with  normal  or  undetermined  bone
arrow.
artial  response
his  is  a  reduction  in  the  SPD  greater  or  equal  to  50%  in  the
ix  initially  most  voluminous  lymph  nodes  in  the  supra  and/or
ub-diaphragmatic  regions  affected.  Hepatic  and  splenic
odules  must  regress  by  at  least  50%  of  the  SPD,  with  no
ew  site  of  disease.
o
g
igure 3. Mantle cell lymphoma, initial CT scan and a monitoring s
esenteric mass (a) Bilateral external iliac lymphadenopathies (b) CT s
ccording to the Cheson criteria (c, d).rovided histopathological diagnosis of recurrence of Hodgkin’s dis-
ase.
table  disease
his  is  deﬁned  as  no  partial  response  or  disease  progression
r  recurrence.Relapse  of  the  disease,  after  complete  response  (Fig.  4).
This  is  the  appearance  of  any  new  lesion  or  increase
reater  or  equal  to  50%  in  the  initial  targets.
can 9 months after treatment: unconﬁrmed complete response.
can after treatment: regression of initial targets evaluated at 95%
Staging  and  monitoring  in  the  treatment  of  lymphomas  149
Table  1  Response  to  treatment  criteria  —  International  Workshop  Criteria  (IWC).
Type  of  response IWC  1999  CT  scan  IWC  2007  CT  and  PET  scans
Complete  response  Normal  PET  scan  becoming  negative  (if  PET0+)  and
CT  scan  normal  (if  PET0-)
Unconﬁrmed  complete  response Reduction  >  75%
Partial  response Reduction  >  50% Reduction  ≥  50%  (CT  scan)  and  PET+  (if  PET0+)
Stability  Reduction  <  50%  Reduction  <  50%  (CT  scan)  and  PET+  (if  PET0+)
Progression/Relapse  New  lesion  >  1.5  cm  or  increase
in  initial  lesion  ≥  50%
New  lesion  >  1.5  cm  or  increase  in  initial
lesion  ≥  50%  and  PET+ (if  PET0+)
PET0: PET scan performed at the time of diagnosis.
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This  occurs  when  any  initially  identiﬁed  lesion  in  non-
responding  patients  or  patients  who  had  a  partial  response
increases  again  by  greater  or  equal  to  50%  of  the  SPD
from  the  nadir,  whether  or  not  accompanied  by  the
appearance  of  new  lesions  during  or  at  the  end  of  treat-
ment.
Response criteria integrating PET: IWC 2007
criteria [9]
The  limits  of  the  1999  IWC  are  due  to  the  incapacity  of
the  CT  scan  to  differentiate  between  viable  tumour  tissue
and  necrosis  and/or  ﬁbrosis  in  residual  masses.  On  the  other
hand,  FDG-PET  metabolic  imaging  is  capable  of  characteriz-
ing  a  viable  tumour  (or  its  absence)  in  residual  masses  with
diagnostic  accuracy  of  80  to  90%.  Consequently,  FDG-PET
better  reﬂects  tumour  response  in  lymphomas  despite  the
poorer  spatial  resolution,  and  is  more  sensitive  than  CT  in
detecting  small  volume  tumours,  including  in  lymph  nodes  of
normal  size  in  a  CT  scan  (i.e.  <  1  cm).  This  is  because  of  bet-
ter  contrast  due  to  intense  uptake  by  certain  pathological
lymph  nodes  relative  to  adjacent  normal  tissues.  In  addition,
the  fusion  of  images  with  a  CT  scan  allows  better  loca-
tion  of  hyperﬁxing  lymph  nodes  by  avoiding  partial  volume
effects.  These  two  imaging  methods  are  complementary  and
for  this  reason  the  new  IWC  2007  criteria  combine  the  mor-
phological  data  of  the  CT  scan  with  the  metabolic  data  of
FDG-PET  (Table  1)  based  on  the  work  of  Juweid  et  al.  in  2005
[8].
Standardisation  of  response  criteria  is  necessary  for
interpreting  and  comparing  clinical  trials,  for  modifying
therapeutic  strategy  during  evolution  of  the  disease  and  for
validating  the  efﬁcacy  of  new  therapeutic  agents.  These
new  2007  recommendations  include  not  only  morphologi-
cal  and  metabolic  imaging  but  also  immuno-histochemistry
and  ﬂow  cytometry,  to  deﬁne  response  in  non-Hodgkin’s  and
Hodgkin’s  lymphomas.  Clinical  and  laboratory  criteria  of  the
bone  marrow  (bone  marrow  biopsy  if  necessary)  are  still
taken  into  account  by  the  haematologist,  while  associating
imaging  criteria.Complete  response
PET  is  negative  at  the  end  of  treatment:  if  a  residual  mass  is
shown  on  the  CT  scan,  irrespective  of  its  size,  the  PET  scan
being  negative  is  enough  to  deﬁne  a  complete  response  in
R
T
t
latients  who  had  a  positive  PET  image  before  treatment,
nd  in  those  who  did  not  have  a  PET  scan  before  treatment
Figs.  5  and  6).
If  the  PET  scan  was  negative  before  treatment  or  if  FDG
xation  is  uncertain  at  the  end  of  treatment,  the  Cheson
999  criteria  apply  with  complete  regression  of  all  ini-
ial  tumour  masses  (normal  lymph  nodes  less  or  equal  to
.5  cm).
It should  be  noted  that  lymph  nodes  with  a  long  axis
easuring  between  1.1  and  1.5  cm  before  treatment  must
ecrease  to  less  or  equal  to  1  cm  in  their  short  axis  following
reatment.
Hepatosplenomegaly  and  all  splenic  or  hepatic  nodules
ave  disappeared:  bearing  in  mind  that  splenic  involvement
s  not  solely  related  to  size,  as  a  normal  size  spleen  can  be
nvaded  by  the  lymphoma.
Cheson’s  1999  unconﬁrmed  complete  response  has  disap-
eared  from  the  response  evaluation:  a  negative  PET  result
s  enough  to  conﬁrm  complete  response  even  when  a  residual
ass  is  present.
artial  response
his  is  deﬁned  as  a  positive  PET  scan  at  the  end  of  treat-
ent  in  at  least  one  initial  site,  in  patients  where  the  PET
can  was  positive  before  the  treatment  (or  in  patients  who
id  not  have  a  PET  scan  before  treatment),  with  a  reduc-
ion  greater  or  equal  to  50%  in  the  SPD  of  initial  lymph  node
asses  (not  more  than  six  targets)  and  absence  of  any  new
ite  (Figs.  7  and  8).  The  other  morphological  criteria  of  a
heson  1999  partial  response  remain  the  same  (non-target
esions,  hepatosplenic  nodules).
PET  is  negative  before  treatment  but  with  uncertain
DG  ﬁxation  at  the  end  of  treatment:  the  CT  scan  crite-
ia  then  deﬁne  the  partial  response,  identical  to  Cheson
999.
table  disease
ET  is  positive  at  the  end  of  treatment  on  the  initial  sites
ith  no  new  sites  in  the  CT  or  PET  scan,  meeting  neither
he  partial  response  criteria  nor  those  of  disease  progres-
ion.elapse  and  disease  progression
his  is  deﬁned  as  the  appearance  of  any  new  lesion  greater
han  1.5  cm  during  or  at  the  end  of  treatment  even  if  other
esions  are  decreasing  in  size.  FDG  uptake  in  a  site  initially
150  B.  Dupas  et  al.
Figure 5. Hodgkin’s disease: bulky mediastinal mass for which the histopathological diagnosis was made after CT-guided biopsy. a, b: CT
scan: voluminous mediastinal mass measuring 14 × 9.5 cm; c: initial PET scan: hypermetabolism conﬁrming supradiaphragmatic lymph node
involvement; d, e: end of treatment CT scan: residual mass measuring 4.2 × 5.2 cm corresponding to an 84% reduction according to the
Cheson criteria, i.e. an unconﬁrmed complete response; f: end of treatment PET scan: considered as a complete response.
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Figure 6. Lymphoma with sub-diaphragmatic involvement. a, b: initial CT scan: voluminous retroperitoneal mass surrounding the ureters
with dilatation of the left renal cavities, combined with left internal iliac lymph node involvement; c, d: end of treatment CT scan after
six courses of chemotherapy: very good response with retroperitoneal residual mass measuring 32 × 15 mm and disappearance of the left
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unaffected  can  only  be  determined  as  relapse  or  progression
after  conﬁrmation  by  a  CT  scan.  New  pulmonary  nodules  on
the  CT  scan  without  any  initial  lymphomatous  pulmonary
lesion  are  usually  benign.  No  therapeutic  decision  should  be
taken  based  solely  on  a  PET  positive  result  without  histolog-
ical  conﬁrmation.
There  must  be  an  increase  greater  or  equal  to  50%  from
the  nadir  in  the  SPD  of  lymph  node  and/or  extranodal
lesions.
Non-measurable  lesions  (effusions,  bone  involvement)
are  recorded  as  present  or  absent.  When  an  FDG-PET  scan
has  not  been  performed  (certain  indolent  lymphomas),  eval-
uation  of  the  response  will  be  made  solely  from  the  CT  scan
on  the  classic  1999  criteria  but  residual  masses  are  consid-
ered  as  a  partial  response.  The  unconﬁrmed  response  status
has  deﬁnitively  been  removed.
Imaging residual masses and
transformation into high-grade lymphoma
The  presence  of  residual  masses  (Fig.  9)  after  chemother-
apy  and/or  radiotherapy  does  not  necessarily  indicate
l
u
t
fto the Cheson criteria, but considered as a complete response with
ersistence  of  the  lymphomatous  condition  [11,12]. This  is  a
ajor  problem  in  interpreting  response  to  treatment,  in  par-
icular  in  the  30  to  50%  of  patients  who  have  a  high  tumour
ass  at  the  initial  diagnosis  (e.g.  a  bulky  mass  >  10  cm).
n  reality,  residual  disease  is  only  present  in  20  to  30%
f  these  patients  [13]. The  contribution  of  PET  is  primor-
ial  in  evaluating  residual  masses:  a  negative  PET  scan
eans  the  absence  of  residual  disease;  a  positive  PET  scan
ndicates  the  sites  of  residual  disease.  A  bulky  mass  is  com-
on  in  Hodgkin’s  disease  and  its  complete  disappearance  is
nusual.  Detection  of  a  viable  tumour  in  sometimes  calci-
ed  residual  lesions  is  impossible  with  a  CT  scan,  hence  the
ecisive  contribution  of  metabolic  imaging.  When  there  is
 dissociated  response,  biopsy  to  conﬁrm  the  diagnosis  his-
ologically  must  be  discussed:  it  may  be  the  same  type  of
ymphoma,  but  chemoresistant,  a  transformation  or,  more
arely,  an  associated  cancer  explaining  the  focalised  non-
esponse,  e.g.  the  persistence  of  a  single  mediastinal  mass
elated  to  concomitant  bronchial  cancer,  while  all  the  other
ymph  node  or  extranodal  sites  have  regressed.  A  resid-
al  mass,  which  is  positive  in  a  PET  scan,  may  not  be  a
umour  but  may  be  granulomatosis,  ﬁbrosis,  or  an  infectious
ocus.  In  all  cases,  however,  PET  can  direct  the  CT-guided
152  B.  Dupas  et  al.
Figure 7. Stage IV Hodgkin’s disease. a: initial CT scan: left anterior mediastinal mass in a left paracardiac pulmonary location; b:
mediastinal hypermetabolism and left pulmonary site conﬁrmed by the PET scan; c: third thoracic vertebral body condensation conﬁrmed
by PET; d: end of treatment CT scan: disappearance of the pulmonary lesion, left anterior mediastinal residual mass reduced by 79%
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iopsy.  Histological  evidence  of  the  progression  or  relapse  of
ny  intercurrent  lesion  is  essential  before  beginning  salvage
reatment.
A  low  grade  non-Hodgkin’s  lymphoma  being  monitored
linically  through  laboratory  values  and  via  CT  scans,  which
s  suspected  of  transforming  into  an  aggressive  lymphoma,
ill  become  positive  in  a  PET  scan  at  a  speciﬁc  site.  It  has
een  demonstrated  that  a  PET  scan  can  effectively  guide  a
iopsy  to  obtain  histological  evidence  of  transformation  into
ichter’s  syndrome  by  measuring  the  standardised  uptake
olume  (SUV),  a  semi-quantitative  parameter,  considered  to
e  a  tumour  grade  biomarker  capable  of  determining  the
esponse  to  treatment  or  transformation  with  a  PPV  of  100%
nd  a  NPV  of  67.3%  for  an  SUV  greater  than  17  [14].
The  CT-guided  biopsy  must  be  performed  under  optimal
onditions:  this  means  CT  guidance  with  precise  pinpointing
n  the  PET  scan  by  fusing  the  images,  several  good  quality
amples  collected  in  a  tube  of  formol,  and  also  a  fresh  sam-
le  for  cryopreservation  sent  immediately  to  the  laboratory
o  obtain  a  complete  analysis.  This  will  include  its  immuno-
istochemistry  and  molecular  biology,  to  type  the  lymphoma
recisely  and  determine  the  appropriate  treatment,  which
ill  be  decided  in  a  multidisciplinary  meeting.
p
r
t hypermetabolism in the PET scan classes the patient as having a
ost-treatment monitoring of lymphomas
nd  estimate of the cumulative radiation
ose
ost-treatment  follow-up  differs  depending  on  whether
linical  trials  or  standardised  clinical  practice  proto-
ols  are  concerned.  It  depends  on  whether  the  initial
bjective  of  the  treatment  is  curative  or  palliative.  Mon-
toring  by  clinical  examination  and  minimum  laboratory
ests  by  the  haematologist  is  primordial:  in  80%  of  cases
t  allows  a  relapse  to  be  diagnosed  (a  palpable  mass,
lteration  in  the  general  condition,  deterioration  of  lab-
ratory  values)  without  the  assistance  of  imaging,  which
ay  be  performed  as  a  second  intention  for  staging  the
elapse,  with  a  PET  scan  if  needed  to  direct  CT-guided
iopsy.
In  clinical  trial  protocols,  CT  scan  monitoring,  once  every
 months  for  2  years,  then  every  6  months  for  3  years,
nd  ﬁnally  annually  for  5  years,  is  recommended  to  assess
rogression-free  survival,  event-free  survival  or  other  crite-
ia  assessing  survival  (Hodgkin’s  cells  or  lymphoma).  On
he  other  hand,  clinical  monitoring  must  be  prolonged  for
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Figure 8. Stage IV Hodgkin’s disease with bone involvement in the PET scan. a, b: CT scan: anterior and middle mediastinal mass;
c,d: CT scan after four courses of treatment: poorly responding patient with a reduction of 63% of the initial mass and persistence of
hypermetabolism in the PET scan thus considered as a partial response, leading to a change in chemotherapy for salvage then an autologous
bone marrow transplant.
Figure 9. Residual mass 2 years after the end of treatment of a diffuse large B cell lymphoma. a: initial CT scan: mediastinal mass of
te re
6
s
a
1
a9 × 8 cm; b: control CT scan after 2 years with a conﬁrmed comple
inactive.
follicular  or  other  indolent  lymphomas.  Imaging  will  depend
on  the  clinical  evolution  [15,16].
Finally,  the  diversity  of  lymphomas  explains  why  the  risks
of  relapse  are  so  variable  from  one  type  of  lymphoma  to
another.  It  is  therefore  difﬁcult  to  establish  general  rules
for  monitoring  applicable  to  all  lymphomas.  Apart  from  in
clinical  trials,  for  the  most  aggressive  lymphomas  (DLBCL,
MCL,  Burkitt’s  lymphoma),  an  imaging  examination  at  3  or
o
t
csponse and a non-evolving residual mass of 2 cm considered to be
 months  then  1  year  after  the  end  of  treatment  is  the
cheme  most  often  suggested.  For  the  more  indolent  forms,
n  imaging  examination  may  be  performed  at  6  months  and
 year.  Beyond  the  ﬁrst  year  after  the  end  of  treatment,
 6-monthly  examination  may  be  suggested.  In  some  types
f  lymphoma,  particularly  the  most  indolent,  it  is  possible
o  alternate  an  ultrasound  examination  and  a  CT  scan.  In
ontrast,  late  relapse  of  some  aggressive  lymphomas  such
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s  DLBCL  is  uncommon.  Wider  spacing  of  examinations  may
herefore  be  discussed  in  some  cases.  The  frequency  of  and
he  imaging  examinations  to  request  thus  depend  on  the
ature  of  the  type  of  lymphoma.  In  current  practice,  despite
oor  efﬁciency  for  screening  relapses,  monitoring  with  a
T  scan  is  performed  every  6  months  for  the  ﬁrst  2  years,
hen  annually.  It  also  screens  for  late  complications  of  the
hemotherapy  and  radiotherapy.
Although  widely  used  for  per  and  post-chemotherapy
valuation,  PET  however  has  no  place  (yet?)  in  monitoring
ymphomas.
Nievelstein  et  al.  [17]  recently  quantiﬁed  the  exposure
o  ionising  radiation  and  the  risk  of  mortality  secondary  to
T  scans  and  PET  in  patients  with  non-Hodgkin’s  lymphoma
nd  Hodgkin’s  lymphoma.  In  children  with  Hodgkin’s  dis-
ase,  the  cumulative  effective  dose  secondary  to  medical
maging  examinations  varied  from  66  Sv  to  113  mSv.  In  adults
ith  non-Hodgkin’s  lymphoma  it  was  a  mean  of  97  mSv.  Mean
maging-related  radio-induced  mortality  was  estimated  [18]
n  children  with  Hodgkin’s  disease  as  0.4%  for  boys  and  0.7%
or  girls  and  in  adults  with  non-Hodgkin’s  lymphoma  as  0.07%
or  men  and  0.09%  for  women.
These  results  conﬁrm  the  necessity  to  reduce  CT  and  PET
cans  in  children  depending  on  the  therapeutic  protocols
19]. Nevertheless,  the  authors  temper  the  results  consid-
ring  the  justiﬁcation  for  imaging  procedures,  for  which  the
isk  of  radio-induced  mortality  is  real  but  modest  in  patients
hose  overall  survival  has  considerably  lengthened  over  the
ast  decades,  with  a  risk  of  mortality  linked  to  the  disease
ery  much  higher  than  the  risk  of  radio-induced  mortality.  In
his  study,  low  dose  CT  scans  were  not  taken  into  account;
heir  protocolled  use  could  contribute  to  decreasing  the  risk
f  diagnostic  medical  irradiation.
The  recent  development  of  whole  body  MRI  in  evaluat-
ng  malignant  lymphoma  is  still  in  the  research  stage  and
lthough  promising,  the  application  of  MRI  on  a  routine
linical  basis  cannot  yet  be  envisaged  as  an  alternative  to
DG-PET,  which  remains  the  reference  examination  [10]  for
he  initial  or  therapeutic  evaluation  of  lymphomas.  Concord-
nce  between  MRI  and  PET  is  moderate  (with  a  mean  of
5%),  with  a  risk  of  over-staging  by  whole  body  diffusion-
eighted  MRI  compared  with  a  PET  scan  [20]. Morphological
nd  functional  MRI  and  metabolic  PET  are  complemen-
ary:  it  is  likely  that  the  next  technological  advances
ombining  MRI  and  PET  will  produce  a  major  change
n  paediatric  oncology  procedures,  in  particular  in  stag-
ng,  re-staging  and  monitoring  the  treatment  of  malignant
ymphomas.
he role of imaging in the therapeutic
trategy for lymphomas
or  the  most  indolent  lymphomas  with  no  clinical  repercus-
ions  or  effect  on  laboratory  values,  such  as  some  follicular
ymphomas,  some  marginal  zone  lymphomas,  or  Walden-
tröm’s  disease,  it  is  possible  to  offer  simple  therapeutic
bstention  with  monitoring.  On  the  other  hand,  for  more
ggressive  lymphomas,  such  as  diffuse  large  B  cell  lym-
homas,  T-phenotype  lymph  node  lymphomas,  or  mantle  cell
ymphomas,  it  is  essential  to  propose  chemotherapy.  The
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ost  common  lymphomas  require  diverse  treatment  options
21].
As  far  as  follicular  lymphoma  (FL)  is  concerned,  the
hoice  of  treatment  strategy  is  based  on  evaluation  of  pro-
nostic  factors,  including  the  number  of  lymph  node  sites
nvolved  (>  4  or  not),  the  stage  (I  or  II  versus  III  or  IV),  or
he  size  of  the  tumour  masses.  To  assess  these  parame-
ers,  a  CT  scan  is  essential.  Depending  on  these  parameters,
herapeutic  abstention  with  monitoring  or  chemotherapy
ith  monoclonal  antibodies  may  be  chosen.  For  the  latter
ption,  six  CHOP  courses  are  often  proposed  followed  by
aintenance  treatment  with  rituximab  spread  over  2  years.
hroughout  the  monitoring  period,  CT  control  scans  are  per-
ormed  possibly  alternating  with  ultrasound  examinations.
ery  often,  relapses  or  progression  in  FL  remain  asymp-
omatic  clinically  or  in  terms  of  laboratory  values,  and  it  is
hen  imaging  that  identiﬁes  the  evolution  and  reactivation  of
he  disease.  It  should  be  noted  that  PET  is  not  formally  indi-
ated  in  this  type  of  lymphoma.  As  for  the  choice  of  ﬁrst  line
reatment,  the  choice  of  relapse  treatment  will  be  based,
mong  other  things,  on  the  imaging  examination,  the  length
f  time  since  the  end  of  the  previous  course  of  treatment,
he  age  of  the  patient,  the  clinical  presentation  and  lab-
ratory  values,  and  comorbidities.  All  therapeutic  options
an  be  discussed,  from  simply  monitoring  to  returning  to
hemotherapy,  and  even  intensiﬁcation  with  an  autologous
ransplant.  It  must  be  remembered  that  FL  is  still  an  incur-
ble  lymphoma  and  is  therefore  quick  to  relapse;  hence  the
mportance  of  monitoring.
As  regards  diffuse  large  B  cell  lymphomas,  treatment  is
lso  based  on  the  combination  of  immunotherapy  (anti-CD20
ntibodies,  rituximab)  and  chemotherapy,  and  the  reference
rotocol  is  also  R-CHOP.  Depending  on  the  staging  (CT  and
ET  scans),  the  laboratory  test  results  and  the  age  of  the
atient,  four  or  eight  courses  of  R-CHOP  chemotherapy  (or
ariants  such  as  R-ACVBP)  are  given,  delivered  every  14
r  21  days.  The  place  for  an  autologous  transplant  as  ﬁrst
ine  treatment  in  diffuse  large  B  cell  lymphomas  can  be
iscussed,  but  the  current  trend  is  to  reserve  autologous
ransplantation  for  relapses  or  for  patients  found  to  be  slow
esponders  on  intermediate  examination  (by  CT  and  PET
can).  Autologous  transplantation  is  based  on  the  collec-
ion  of  a  haemopoietic  stem  cell  transplant,  usually  from
 venous  sample.  More  intense  chemotherapy  is  then  given
ausing  prolonged  aplasia  of  about  ten  days.  The  period  of
ecovery  from  aplasia  is  reduced  by  reinjecting  the  trans-
lant,  normally  48  h  after  the  end  of  chemotherapy.  This  is
 treatment  based  on  the  administration  of  chemotherapy
ver  a  short  period  of  time  and  the  autologous  transplant  is
nly  a  support  to  reduce  the  duration  of  aplasia  and  there-
ore  the  risk  of  infection.  Unlike  in  FL,  relapses  are  usually
arly  with  this  type  of  lymphoma  and  become  rarer  once
eyond  the  ﬁrst  year  after  the  end  of  treatment.  A  CT  scan
s  the  standard  examination  for  monitoring.
As  far  as  mantle  cell  lymphomas  are  concerned,  the  sit-
ation  is  different.  An  autologous  transplant  is  given  as  a
rst  line  of  treatment  to  patients  less  than  65  years  old  fol-
owing  reduction  in  the  tumour  mass  by  chemotherapy  plus
mmunotherapy.  In  older  patients,  again  R-CHOP  chemother-
py  is  preferred,  and  is  followed  by  maintenance  treatment
ith  rituximab.  As  in  FL,  it  is  an  incurable  condition  with
ate  relapses  occurring  sometimes  more  than  5  years  after
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necessarily  indicate  persistence  of  the
lymphomatous  disease:  a  negative  PET  scan  means
the  absence  of  residual  disease.
• Aggressive  lymphomas  —  DLBCL,  Burkitt’s  lymphoma,
etc.  —  are  very  chemosensitive  and  rarely  relapse
later,  whereas  indolent  lymphomas  (follicular
lymphoma,  etc.)  are  usually  chemosensitive  but
have  a  tendency  to  relapse  in  the  more  or  less
long  term,  hence  the  importance  of  monitoring
haematological  and  laboratory  values,  and  clinical
evolution.  This  will  help  assess  the  appropriateness
of  a  CT  scan  or  ultrasound  examination  some  time
after  the  end  of  treatment.
• Low  dose  CT  scans  should  allow  the  secondary
cumulative  effective  dose  to  be  reduced,
particularly  in  children.
• Wise  and  optimal  use  of  multimodal  imaging  implies
multidisciplinary  consultation  and  constant  dialogue
between  radiologists,  specialists  in  nuclear  medicine
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the  end  of  treatment.  A  CT  scan  is  the  standard  examina-
tion  for  staging,  for  the  end  of  treatment  examination  and
for  monitoring.
As  regards  Hodgkin’s  lymphoma,  a  CT  scan  combined  with
a  PET  scan  is  essential  and  allows  a  decision  to  be  made  con-
cerning  therapeutic  options.  The  choice  of  chemotherapy
(most  often  ABVD  or  BEACOPP),  the  number  of  courses  to
administer  and  additional  irradiation  depend  on  the  results
of  this  examination.  CT  and  PET  scans  also  allow  interme-
diate  response  and  the  end  of  treatment  response  to  be
evaluated.  Only  CT  scans  will  be  used  for  monitoring,  not
PET.
These  four  cases  of  lymphoma  illustrate  the  importance
of  having:
• a good  histological  diagnosis  so  that  suitable  treatment
can  be  proposed  (the  role  of  the  biopsy);
• complete  staging  (the  role  of  CT  scans,  but  also  PET  just
for  certain  lymphomas);
• a complete  end  of  treatment  examination  (CT  and  PET
scans)  and  then  of  organising  suitable  monitoring  (CT
scans  and  ultrasound  examinations).
Conclusion
Computed  tomography,  like  all  conventional  imaging  (ultra-
sonography,  thoracic  X-rays)  is  involved  in  all  the  stages  of
managing  lymphomas,  from  the  diagnosis  through  staging  to
follow-up  monitoring.  The  growing  emergence  of  metabolic
imaging  may  lead  to  the  belief  that  CT  and  ultrasonography
have  been  relegated  to  second  place.  Attentive  reading  of
the  most  recent  literature  rapidly  refutes  this  impression.  It
appears,  above  all,  that  wise  and  optimal  use  of  multimodal
imaging  techniques  implies  multidisciplinary  consultation
and  constant  dialogue  between  radiologists,  specialists  in
nuclear  medicine  and  haematologists.
TAKE-HOME  MESSAGES
• The  diagnosis  and  therapeutic  management  of
lymphomas  require  a  surgical  or  CT-guided  biopsy  of
optimal  quality.
• The  examination  systematically  comprises  a  CT  scan
of  the  cervical,  thoracic  and  abdominopelvic  regions,
with  injection  of  a  contrast  agent;  according  to  the
international  recommendations,  PET  is  indicated  for
staging  lymphomas  that  have  high  avidity  for  FDG:
diffuse  large  B  cell  lymphomas  (DLBCL)  and  Hodgkin’s
disease.
• For  characterizing  lesions,  CT  and  PET  scans
are  complementary,  with  the  metabolic  imaging
directing  a  CT-guided  biopsy  by  identifying  residual
masses  or  for  authenticating  the  transformation  of
an  indolent  into  a  high-grade  lymphoma.
• The  Cheson  1999  criteria  have  been  replaced  by
the  IWC  2007  criteria  integrating  the  CT  scan’s
morphological  criteria  and  FDG-PET’s  metabolic
response.  The  presence  of  residual  masses  following
chemotherapy  and/or  radiotherapy  does  not p
n
w
band  haematologists.
linical case
n  a  60-year-old  patient  with  a  pleural  effusion,  cells  were
iscovered  corresponding,  on  cytological  analysis  of  the
iopsy  liquid,  to  follicular  lymphoma  (Figs.  10  —12).
uestions
.  What  initial  staging  would  you  recommend?
2.  A  PET  scan  conﬁrmed  supra  or  sub-diaphragmatic
ymph  node  involvement  and  a  semi-quantitative  study  of
UV.max  found  a  more  hypermetabolic  lesion  in  the  left
xternal  iliac  area,  with  an  SUV.max  of  40.6.  What  does  this
alue  suggest  to  you?
3. A  biopsy  is  recommended.  Which  mass  would  you
iopsy?
4.  What  diagnostic  evolution  would  you  suspect  in  this
atient?
nswers
.  Staging  systematically  includes  a  CT  scan  of  the  cervical,
horacic  and  abdominopelvic  regions  following  injection  of  a
ontrast  agent.  Except  in  particular  therapeutic  protocols,
ET  is  not  indicated  as  a  ﬁrst  course  of  action  in  follicular
ymphoma.  However,  this  patient  was  included  in  a  protocol
equiring  an  initial  PET  evaluation.
2.  This  high  SUV.max  value  of  40.6  leads  to  aggressive
ransformation  of  the  lymphoma  being  suspected  in  the  left
xternal  iliac  area.
3.  The  left  iliac  mass,  which  is  the  most  hypermetabolic
n  the  PET  scan,  should  therefore  be  biopsied,  but  also  the
osterior  mediastinal  lesion,  to  conﬁrm  the  initial  diagnosis
f  follicular  lymphoma.
4.  Histopathological  examination  of  the  left  iliac  lym-
hadenopathy  showed  a  grade  3a  follicular  lymphoma  (the
umber  of  centroblasts  is  very  high  within  the  nodules)  but
ith  a  few  centrocytic  cells  persisting  it  is  prevented  from
eing  classed  as  grade  3b.  Histopathological  examination  of
156  B.  Dupas  et  al.
Figure 10. Axial contrast-enhanced CT shows left pleural effusion and left iliac lymph node.
Figure 11. a,b: PET/CT: FDG-avid mediastinal and left iliac masses.
Figure 12. a,b: PET/CT: FDG-avid mediastinal and left iliac masses.
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the  right  posterior  mediastinal  lymphadenopathy  showed  a
grade  2/3a  follicular  lymphoma.  Consequently  it  was  not
a  transformation  into  a  diffuse  large  B  cell  lymphoma,  but
despite  everything  —  because  of  the  suspected  left  iliac
aggressive  component  in  the  PET  scan  and  the  aggres-
sive  clinical  presentation  for  a  follicular  lymphoma  —the
chemotherapy  was  intensiﬁed  to  R-CHOP  (though  stopped
short  of  autologous  transplantation  as  there  was  no  his-
tological  evidence).  That  also  meant  that  the  method  of
evaluating  the  response  of  this  follicular  lymphoma  to  treat-
ment  was  modiﬁed,  with  an  intermediate  PET  scan  and  a
PET  and  CT  scan  at  the  end  of  treatment.  This  observation
illustrates  the  importance  of  histological  evidence,  which
is  essential  to  conﬁrm  the  transformation  of  a  lymphoma
before  envisaging  treating  it.  It  also  highlights  the  inﬂuence
of  PET  scans  on  the  treatment  and  monitoring  method.
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